IMPACT-HTN Study of Patients With Hypertension
Key facts
- Where
- Durham and Palo Alto, United StatesSee the 2 sites
Where in United States
- Duke University HospitalDurham, United StatesNo longer taking part
- Stanford University Hypertension CenterPalo Alto, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vivek Bhalla
- Trial code
- NCT07579260
- Record updated
- 29 June 2026
- Original description
An estimated 120 million people have high blood pressure (hypertension) in the US, of which approximately 10% have resistant hypertension. This study aims to enroll patients who continue to have hypertension while being treated with at least two medications. The study will follow patients for approximately 3 months and collect real-world information on changes in their health to identify an ideal patient profile that would benefit from 4th-line antihypertensive therapies, including, but not limited to, FDA-approved aprocitentan, renal denervation, mineralocorticoid receptor antagonists, etc.Read full original descriptionShow less
Prospective Early Patient Experience Initiative (IMPACT-HTN)
An estimated 120 million people have high blood pressure (hypertension) in the US, of which approximately 10% have resistant hypertension. This study aims to enroll patients who continue to have hypertension while being treated with at least two medications. The study will follow patients for approximately 3 months and collect real-world information on changes in their health to identify an ideal patient profile that would benefit from 4th-line antihypertensive therapies, including, but not limited to, FDA-approved aprocitentan, renal denervation, mineralocorticoid receptor antagonists, etc.
Inclusion: Signed and dated informed consent form; Ability to answer survey questions and to report blood pressure reading monthly; Male and female participants; 18 years or older; Treated with at least 2 antihypertensive therapies of different pharmacological classes for at least 4 weeks before the screening visit; Mean Sitting Systolic Blood Pressure (SiSBP) greater or equal to 130 mmHg.
Exclusion: Confirmed severe hypertension (grade 3) defined as SiSBP greater than or equal to 180 mmHg and/or Sitting Diastolic Blood Pressure (SiDBP) greater than or equal to 110 mmHg; Clinically significant unstable cardiac disease at screening or in the past in the opinion of the investigator; Heart failure NYHA functional class III and IV or NT-proBNP > 500 pg/mL; Severe renal insufficiency or eGFR < 15 mL/min/1.73m2; Moderate to severe hepatic impairment (Child-Pugh B and C) or elevated aminotransferase (> 3 x ULN).